During this 60-minute webinar, expert speakers Kimberly Hoy, JD, CPC, and Valerie Rinkle, MPH, CHRI, will explain how to navigate compliance with off-campus provider-based department (PBD) regulations, including recent changes to regulatory guidance and requirements, how to navigate deadlines...
A bipartisan group of senators introduced a bill in early August to clarify requirements, increase oversight, and reform the payment and data infrastructure of the 340B Drug Pricing Program.
CMS is moving forward with it’s plans for a mandatory nationwide rollout of the Comprehensive Joint Replacement Expanded (CJR-X), according to the 2027 Inpatient Prospective Payment System (IPPS) final rule.
CMS recently launched the Medicare GLP-1 Bridge, a short-term demonstration that provides eligible Part D beneficiaries with access to certain glucagon‐like peptide‐1 (GLP-1) drugs.
Denials rarely start at the payer. They often begin upstream, in the gaps between clinical, financial and quality workflows, where teams may be aligned in purpose but disconnected by process. In this fireside chat healthcare leaders...
CMS is considering fundamental changes to how it pays for professional services, according to the 2027 Medicare Physician Fee Schedule (MPFS) proposed rule. The proposed rule, released July 14, describes numerous potential changes to payments, codes, coverage, and more.
Hospitals could be facing lower reimbursement for non-drug items and services, 340B drugs, excepted off-campus provider-based department (PBD) services, as well as additional price transparency and prior authorization requirements, according to CMS’ 2027 Outpatient Prospective Payment System (OPPS) proposed rule.
